
|Articles|October 1, 2012
Unapproved neurotoxins abound, dermatologist warns
The approval of the newest botulinum toxin product available in the United States underscores the value of the Food and Drug Administration drug approval process and the importance of using branded products, says Mich?l H. Gold, M.D.
Advertisement
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Lebrikizumab Enters Late-Stage Testing for Nummular Eczema
2
The Weekly Roundup: January 12-16
3
Subgroup Analysis Demonstrates Efficacy of Roflumilast Cream for AD in Pediatric Patients With Diverse Skin Types
4
Graham Heap, MBBS, PhD, Discusses Positive Phase 3 Results for Zasocitinib
5


















